Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GALECTIN THERAPEUTICS INCGALT · Entity 5577 | Director | January 16, 2019 | January 18, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GALECTIN THERAPEUTICS INC
Report date January 16, 2019 · Filed January 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.72 · Expires 2029-01-16 | Direct | 25,000 |
Reported balance
After 2019-01-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-16 · Grant · Acquired 25,000 · Balance 25,000 F1: The options vest 100% on January 16, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest 100% on January 16, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 16, 2019 Filed Jan 18, 2019 22:19 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001179022-19-000015 · edgar.xml · derivative · entry 1 SHULMAN STEPHEN · CIK 0001725594 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common stock · 25,000 shares Expires 2029-01-16 F1 · derivative.exercise_date: The options vest 100% on January 16, 2020. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 21:13 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 46,875 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001179022-17-000081 · edgar.xml · derivative · entry 1 SHULMAN STEPHEN · CIK 0001725594 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,875 Underlying: Common stock · 46,875 shares Expires 2027-12-14 F1 · derivative.exercise_date: The options vest 100% on December 14, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.